Vaccination Considerations for Cosentyx Users
Cosentyx, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, is a biologic medication used to treat various autoimmune diseases, including psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [1]. As with any immunosuppressive therapy, Cosentyx users are at a higher risk of infections and should follow specific vaccination guidelines to ensure their safety.
Live Vaccines and Cosentyx Use
The primary concern for Cosentyx users is the potential for reduced immune responses to live vaccines, such as the MMR (measles, mumps, and rubella), chickenpox, and shingles vaccines. Live vaccines work by exposing the body to a weakened or mild form of the virus, which helps stimulate an immune response. However, in immunocompromised individuals, the risk of the vaccine itself causing disease is greater than the benefits of vaccination.
The Centers for Disease Control and Prevention (CDC) and the manufacturer of Cosentyx recommend that patients receiving live vaccines avoid taking Cosentyx for at least 1 month before and 1 month after vaccination. In some cases, the CDC may recommend administering live vaccines before starting Cosentyx, especially in situations where the benefit of vaccination outweighs the risks.
Non-Live Vaccines and Cosentyx Use
In contrast, non-live vaccines, such as inactivated or conjugate vaccines (e.g., flu, pneumococcal, and HPV vaccines), do not pose the same risks as live vaccines and can be safely administered to Cosentyx users. These vaccines are generally made from inactivated pathogens or specific components of the pathogen, which cannot cause disease themselves.
How Frequently Are Vaccinations Needed During Cosentyx Use?
While Cosentyx users should adhere to specific vaccination guidelines, the frequency of vaccinations required depends on various factors, including the individual's health status, previous vaccinations, and the specific type of vaccine recommended.
It is essential for patients receiving Cosentyx to consult with their healthcare provider or a specialist in immunology to determine the best vaccination schedule for their needs. Healthcare providers may recommend a vaccination schedule tailored to the individual's specific situation, which may involve administering a limited number of live vaccines outside of the recommended 1-month window or using alternative non-live vaccines.
Who to Consult for Personalized Vaccination Guidance
To ensure the best possible protection from infections and optimal Cosentyx use, patients should discuss their vaccination needs with their healthcare provider, an immunologist, or a specialist in infectious diseases. These experts will be able to provide personalized guidance on the most suitable vaccination schedule and any necessary precautions for maintaining a healthy immune system during Cosentyx therapy.
Sources:
[1] DrugPatentWatch.com, Cosentyx (secukinumab)
https://www.drugpatentwatch.com/nda/2014/DSC-2013-2016-COSENTYL-secukinumab-IL-17-receptor-inhibitor-COSENTYX-Secukinumab-FH-202-COS-COS-2022-Cosentyx-Secukinumab/
Recommended readings for related vaccine information: CDC.gov